GLP-1 and Cardiovascular Risk Reduction: The Clinical Evidence You Should Know

The cardiovascular story of GLP-1 medications has transformed them from weight loss drugs into cardiometabolic interventions with implications far beyond the scale. The SELECT trial's demonstration of a 20% reduction in major adverse cardiovascular events positioned semaglutide alongside statins and SGLT2 inhibitors as a pillar of cardiovascular risk management in patients with obesity. Here's what clinicians and patients should know.

The SELECT Trial: Landmark Results

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a randomized, double-blind, placebo-controlled trial enrolling 17,604 adults aged 45 or older with overweight or obesity (BMI ≥27), established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease), and no diabetes.

The primary endpoint was time to first major adverse cardiovascular event (MACE) — a composite of cardiovascular death, non-fatal heart attack, or non-fatal stroke. After a median follow-up of 39.8 months:

• MACE occurred in 6.5% of patients receiving semaglutide versus 8.0% on placebo — a 20% relative risk reduction
• The benefit was consistent across age groups, sexes, baseline BMI levels, and geographic regions
• Cardiovascular death alone showed a trend toward reduction (numerically lower but not individually statistically significant)
• Heart attack and stroke were both individually reduced

What makes SELECT uniquely important is its patient population: these were people with obesity and cardiovascular disease but without diabetes. Prior cardiovascular outcome trials (SUSTAIN 6, PIONEER 6) demonstrated similar benefits in patients with type 2 diabetes. SELECT extended the cardiovascular protection to the broader population with obesity, fundamentally expanding who stands to benefit.

Mechanisms of Cardiovascular Protection

The cardiovascular benefits of GLP-1 medications appear to operate through multiple pathways, some weight-dependent and some weight-independent:

Blood pressure reduction: Semaglutide produces modest but consistent blood pressure reductions of approximately 3-5 mmHg systolic. While modest in absolute terms, population-level blood pressure reductions of this magnitude are associated with meaningful reductions in stroke and heart failure.

Lipid improvement: GLP-1 agonists reduce triglycerides by 15-25% and modestly improve LDL and HDL cholesterol. The triglyceride reduction is particularly relevant for cardiovascular risk, as elevated triglycerides are an independent risk factor that is often undertreated.

Anti-inflammatory effects: GLP-1 medications reduce markers of systemic inflammation, including C-reactive protein (CRP) and interleukin-6. Chronic low-grade inflammation is increasingly recognized as a key driver of atherosclerotic cardiovascular disease, and GLP-1-mediated inflammation reduction may be a major contributor to the cardiovascular benefit.

Direct vascular effects: GLP-1 receptors are present in vascular endothelium and smooth muscle. Preclinical studies suggest that GLP-1 receptor activation improves endothelial function, reduces oxidative stress in blood vessels, and may slow atherosclerotic plaque progression.

Weight loss itself: While weight loss contributes to cardiovascular improvement, the speed and magnitude of the cardiovascular benefit in SELECT — apparent within the first year — suggest that weight-independent mechanisms play a significant role.

Heart Failure: Emerging Evidence

The GLP-1 and heart failure story has evolved significantly. The STEP-HFpEF trial demonstrated that semaglutide improved symptoms, physical function, and exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. Patients experienced significant improvement in the Kansas City Cardiomyopathy Questionnaire score (a measure of heart failure symptoms and quality of life), as well as greater weight loss and improved 6-minute walk distance.

This is particularly noteworthy because HFpEF is one of the most treatment-resistant cardiovascular conditions, and many patients with HFpEF have comorbid obesity that contributes to their symptoms. GLP-1 medications may address both the heart failure and the obesity simultaneously.

Who Benefits Most: The Clinical Profile

Based on the available evidence, the patients who stand to benefit most from GLP-1 cardiovascular protection include:

• Patients with established cardiovascular disease (prior MI, stroke, PAD) and BMI ≥27 — the SELECT population
• Patients with type 2 diabetes and high cardiovascular risk — supported by SUSTAIN 6, PIONEER 6, and other diabetes CVOTs
• Patients with HFpEF and obesity — supported by STEP-HFpEF
• Patients with chronic kidney disease — supported by the FLOW trial (cardiorenal benefit)
• Patients with multiple metabolic risk factors (obesity + hypertension + dyslipidemia + inflammation) — though formal CVOT data in primary prevention is still pending